Synergistic effect of olaparib (AZD2281) with combination of cisplatin on PTEN-deficient lung cancer cell lines

被引：0
作者：
Minami, Daisuke [1 ]
Takigawa, Nagio [2 ]
Takeda, Hiromasa [3 ]
Takata, Minoru [4 ]
Ichihara, Eiki [1 ]
Hisamoto, Akiko [1 ]
Hotta, Katsyuyuki [1 ]
Tabata, Masahiro [1 ]
Tanimoto, Mitsune [1 ]
Kiura, Katsuyuki [1 ]
机构：
[1] Okayama Univ Hosp, Okayama, Japan
[2] Kawasaki Med Sch, Okayama, Japan
[3] Tottori Municipal Hosp, Tottori, Japan
[4] Kyoto Univ, Kyoto, Japan
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-4686
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4686
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
    Xie, Kejie
    Ni, Xiaoyan
    Lv, Shanmei
    Zhou, Guozhong
    He, Honger
    ONCOLOGY LETTERS, 2021, 21 (05)
  • [32] DNA repair suppression and effect of cisplatin in mesothelioma and lung cancer cell lines
    Roe, Oluf D.
    Chen, Wu
    Zhi, Xiaofei
    Chen, Duan
    Chen, Yijiang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
    Panagiotis Apostolou
    Maria Toloudi
    Marina Chatziioannou
    Eleni Ioannou
    Dennis R Knocke
    Joe Nester
    Dimitrios Komiotis
    Ioannis Papasotiriou
    BMC Pharmacology and Toxicology, 14
  • [34] Synergistic antitumor effect of the combination of a dual cancer-specific oncolytic adenovirus and cisplatin on lung cancer cells
    Jin, Jing
    Zhu, Yilong
    Sun, Fei
    Chen, Zhifei
    Chen, Shuang
    Li, Yiquan
    Li, Wenjie
    Li, Min
    Cui, Chuanxin
    Cui, Yingli
    Yin, Xunzhi
    Li, Shanzhi
    Zhao, Jin
    Yan, Guo
    Li, Xiao
    Jin, Ningyi
    ONCOLOGY LETTERS, 2018, 16 (05) : 6275 - 6282
  • [35] Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
    Apostolou, Panagiotis
    Toloudi, Maria
    Chatziioannou, Marina
    Ioannou, Eleni
    Knocke, Dennis R.
    Nester, Joe
    Komiotis, Dimitrios
    Papasotiriou, Ioannis
    BMC PHARMACOLOGY & TOXICOLOGY, 2013, 14
  • [36] Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL)
    Garcia Campelo, Rosario
    Felip, Enriqueta
    Massuti, Bartomeu
    Majem, Margarita
    Carcereny Costa, Enric
    Palmero, Ramon
    Angel Molina-Vila, Miguel
    Martinez, Pablo
    Luis Marti-Ciriquian, Juan
    Alonso-Jaudenes Curbera, Guillermo
    Pallares, Cinta
    Cardenal, Felipe
    Carmen Gonzalez-Arenas, Maria
    Mayo-de las Casas, Clara
    Sanchez-Ronco, Maria
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro
    Mogi, H
    Hasegawa, Y
    Watanabe, A
    Nomura, F
    Saka, H
    Shimokata, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (03) : 199 - 204
  • [38] mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
    Kim, Eun Ju
    Jeong, Jae-Hoon
    Bae, Sangwoo
    Kang, Seongman
    Kim, Cheol Hyeon
    Lim, Young-Bin
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (06) : 1248 - 1256
  • [39] The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
    Lallo, Alice
    Frese, Kristopher K.
    Morrow, Christopher J.
    Sloane, Robert
    Gulati, Sakshi
    Schenk, Maximillian W.
    Trapani, Francesca
    Simms, Nicole
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L.
    Priest, Lynsey
    Hughes, Adina
    Lai, Zhongwu
    Cadogan, Elaine
    Khandelwal, Garima
    Simpson, Kathryn L.
    Miller, Crispin
    Blackhall, Fiona
    O'Connor, Mark J.
    Dive, Caroline
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5153 - 5164
  • [40] Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines
    Fujita, M
    Tsuchida, T
    Higashino, K
    ANTI-CANCER DRUGS, 1999, 10 (01) : 119 - 127
12345